Endothelial dysfunction in renal transplant patients is closely related to serum cyclosporine levels

Transplantation Proceedings
F MercanogluM S Sever

Abstract

Cyclosporine (CsA), one of the standard agents used in renal transplant recipients, has been considered to cause endothelial dysfunction and to contribute to arterial complications posttransplant. Since concentration-dependent effects of CsA on endothelial functions in humans have not been examined, this study was performed to investigate this relationship. Fifteen renal transplant patient and 20 healthy subjects (controls) were evaluated for brachial artery endothelial function using high-resolution vascular ultrasound just before the CsA dosage (baseline) and at the second hour after the administration. Endothelium-dependent and -independent vasodilatations (EDD and EID, respectively) were assessed by establishing of the responses to reactive hyperemia and by using sublingual nitroglycerine, respectively. CsA levels were assessed at baseline and at second hour, times when performing brachial artery measurements. There were no significant differences between recipients and controls with respect to atherosclerosis risk factors. Mean EDD of recipients at baseline times were significantly less than those in controls (9.1% +/- 5.5% vs 15.2% +/- 7.2%, respectively; P < .001). CsA levels at trough and at second hour were 153.9 +/- 7...Continue Reading

References

Nov 1, 1995·Journal of the American College of Cardiology·T J AndersonA C Yeung
Apr 8, 1999·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·S AakhusT E Widerøe
Sep 28, 2000·Current Opinion in Immunology·C DambrinR E Morris
Jun 8, 2001·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·C H BoltonJ H Pinkney
Jan 15, 2002·Journal of the American College of Cardiology·Mary C CorrettiUNKNOWN International Brachial Artery Reactivity Task Force
Jun 5, 2003·Clinical Transplantation·Huseyin OflazMehmet S Sever

❮ Previous
Next ❯

Citations

Apr 5, 2011·Bone Marrow Transplantation·E Carreras, M Diaz-Ricart
Mar 12, 2011·International Journal of Clinical Pharmacy·D G HornG Hempel
Jul 6, 2010·Pharmacology & Therapeutics·Maaike KockxLeonard Kritharides
Jun 20, 2008·The Journal of Surgical Research·Mark LaSpinaDilip S Kittur
Jun 12, 2010·Transplant International : Official Journal of the European Society for Organ Transplantation·Robinson JoannidesMichel Godin
Feb 1, 2013·Transplantation·Dag Olav DahleAnders Asberg
Feb 24, 2007·Transplantation·Kayser CaglarMujdat Yenicesu
Apr 23, 2020·Frontiers in Immunology·Francesca BonifaziAntonio Colecchia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.